This document is a guideline and narrative review focused on kidney transplant recipients. It discusses the management of post-transplant diabetes mellitus and type 2 diabetes without reporting specific study results or sample sizes. The text serves as a summary of existing knowledge rather than new evidence.
The review covers immunosuppressive therapy used to prevent organ rejection. Medications mentioned include calcineurin inhibitors, corticosteroids, mTOR inhibitors, and tacrolimus. These drugs are central to the discussion regarding diabetes risks. The document outlines how these treatments relate to metabolic health in this specific group.
Safety data such as adverse events or discontinuations are not reported in this summary. There are no specific findings on how these treatments change outcomes. Readers should understand this is a general overview rather than new clinical trial data. The lack of reported results means specific risks are not quantified here.
Patients should discuss their specific situation with a healthcare provider. Medical decisions depend on individual health needs and current medical standards. This information serves as a reference for understanding treatment contexts. Always consult a professional before making changes to medication.